Metformin as a Treatment Strategy for Sjögren's Syndrome.
Level 5 - mechanism / opinion, no new human data
Narrative review of proposed biological mechanisms without primary clinical data
PubMed 34281285 · doi:10.3390/ijms22137231
What was done
Narrative review outlining the mechanistic rationale for repurposing metformin as a therapeutic strategy in Sjögren's syndrome, focusing on cellular and immunomodulatory pathways.
What was found
The abstract reports no empirical numbers or clinical trial data. It describes the biological pathway whereby metformin inhibits mitochondrial complex I, activates AMPK, and suppresses mTOR, thereby favoring regulatory T-cell differentiation and reducing B-cell differentiation into antibody-producing plasma cells.
Why it matters
Because effective disease-modifying treatments for Sjögren's syndrome remain limited, repurposing metformin to modulate pathogenic immune responses represents a plausible therapeutic concept.
Limits
The abstract provides only theoretical and mechanism-based reasoning; no patient cohort, sample size, or clinical efficacy data regarding salivary gland function are reported.
Cited by
- supports Metformin activates AMPK by inhibiting ATP production through the mitochondrial respiratory chain.